[Intermediate-dose cytosine arabinoside therapy in refractory acute leukemia].
Ohshima
A
A
Third Dept. of Internal Medicine, Akita University School of Medicine.
Yoshida
K
K
Miyazaki
S
S
Fukushima
Y
Y
Miura
A B
AB
Endo
K
K
Ando
H
H
Sasaki
H
H
Saito
S
S
Sato
I
I
D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D001215:Asparaginase